Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 04, 2022 11:29am
147 Views
Post# 34281773

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Possible chinese partner?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Possible chinese partner?That selling has been on low volume so my best guess is it is related to people who focus more on the stock price movements to determine their mood (check your mirror!) than on fundamentals. Clearly, the larger shreholders are not unloading the stock given the low trading volume. 

We are most likely now very close to hearing some fundamental news on the phase 1a. All indications we have from how the drug performed in the rpeclinical trials, to the length of time this trial has gone on to the various actions taken by the company recently hint pretty strongly that there will be something good coming from the phase 1a report.

So, my advice is to stop looking at the share price which is currently being determined by investors who know little about TH's real situation and try to be patient just a little longer. There is a decent chance you will be rewarded to some degree for that patience. 

Bucknelly21 wrote: Gotta love bringing in the new year with 2 days of red and more selling 


<< Previous
Bullboard Posts
Next >>